These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12720151)

  • 1. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.
    Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R
    Semin Oncol; 2003 Apr; 30(2):270-4. PubMed ID: 12720151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.
    Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N
    Semin Oncol; 2003 Apr; 30(2):265-9. PubMed ID: 12720150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
    Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J
    Leuk Lymphoma; 2002 Sep; 43(9):1777-82. PubMed ID: 12685831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
    Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
    Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Plasmati R; Cangini D; Tacchetti P; Perrone G; Pastorelli F; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2005 Mar; 74(3):212-6. PubMed ID: 15693790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
    Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
    J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
    Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Zervas K; Tsatalas C; Kokkinis G; Repoussis P; Symeonidis A; Delimpasi S; Katodritou E; Vervessou E; Michali E; Pouli A; Gika D; Vassou A; Terpos E; Anagnostopoulos N; Economopoulos T; Pangalis G
    J Clin Oncol; 2007 Aug; 25(22):3344-9. PubMed ID: 17577016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
    Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
    Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.